Pharmacogenomics and adverse drug reactions: the case of statins

Bibliography

• International human genome sequencing consortium. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921
   PubMed Web of Science ®Google Scholar
• Daly AK. Pharmacogenetics and human genetic polymorphisms. Biochem J 2010;429:435-49
   PubMed Web of Science ®Google Scholar
• Tohkin M, Ishiguro A, Kaniwa N, Prediction of severe adverse drug reactions using pharmacogenetic biomarkers. Drug Metab Pharmacokinet 2010;25(2):122-33
   PubMedGoogle Scholar
• Bai JP. Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics. Drug Metab Pharmacokinet 2010;25(1):62-71
   PubMedGoogle Scholar
• Malhey RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LL, Lazo JS, Parker KL, editors, Goodman & Gilman's the pharmacological basis of therapeutics. 11th edition. McGraw Hill, New York; 2006. p. 933-66
   Google Scholar
• Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Mills EJ, Rachlis B, Wu P, Primary prevention of cardiovascular mortality and events with statin treatments. A network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52(22):1769-81
   PubMedGoogle Scholar
• Ridker PM, Danielson E, Fonseca FAH, ; for the Jupiter Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• Yusuf S, Lonn E, Bosch J. Lipid lowering for primary prevention. Lancet 2009;373:1152-5
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K, European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehabil 2007;14(Suppl 2):E1-40
   PubMed Web of Science ®Google Scholar
• Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90
   PubMed Web of Science ®Google Scholar
• Strandberg TE, Pyorala PK, Cook TJ, Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364:771-7
   PubMed Web of Science ®Google Scholar
• Long-term eff ectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002;359:1379-87
   PubMed Web of Science ®Google Scholar
• Davidson MH, Clark JA, Glass LM, Statin safety: an appraisal from the adverse events reporting system. Am J Cardiol 2006;97(Suppl):32C-43C
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Clark JM. The epidemiology of non-alcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40(Suppl 1):S5-10
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Gossios TD, Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver function tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-22
   Google Scholar
• Bader T. Liver test are irrelevant when prescribing statins. Lancet 2010;376:1882-3
   Google Scholar
• Kinlay S, Schwartz GC, Olsson Ag, Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study. Circulation 2004;110:386-91
   PubMed Web of Science ®Google Scholar
• Newman C, Tsai J, Szrarek, Comparative safety of atorvastatin 80 mg versus 10 mg deriverd from analysis of 49 compared trials in 14,236 patients. Am J Cardiol 2006;97:61-7
   PubMed Web of Science ®Google Scholar
• deLemos JA, Blazing MA, Wiviott SD, Early intensive vs. delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16
   PubMed Web of Science ®Google Scholar
• Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf 2007;6(6):673-84
   PubMedGoogle Scholar
• Thompson PD, Clarkson PM, Rosenson PS. An assessment of statin safety from muscle experts. Am J Cardiol 2006;97(Suppl):69C-76C
   Google Scholar
• Pasternak RC, Smith SC, Bairey-Merz CN, ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Corsini A, Davidson MH, Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553-64
   PubMed Web of Science ®Google Scholar
• Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150:858-68
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Keech A, Sacks FM, Safety and tolarebility of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002;105:2341-6
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez LA, Gonzalez-Perez A, Stang MR, The safety of rosuvastatin in comparison with other statins in over 25000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf 2008;17:953-61
   PubMedGoogle Scholar
• Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32225 diabetic and non-diabetic patients. Clin Ther 2007;29:1761-70
   Google Scholar
• Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis 2010;210:337-43
   PubMed Web of Science ®Google Scholar
• Ho PM, Magid DJ, Shetterly SM, Medication non-adherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008;155:772-9
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther 2005;19(6):403-14
   PubMed Web of Science ®Google Scholar
• Vladutiu GD, Simmons Z, Isackson PJ, Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34:153-62
   PubMed Web of Science ®Google Scholar
• Vladutiu GD. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008;20:648-55
   PubMed Web of Science ®Google Scholar
• Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2010;87(1):130-3
   PubMedGoogle Scholar
• Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007;8:787-802
   PubMed Web of Science ®Google Scholar
• Atorvastatin, Lovastatin, simvastatin pharmacokinetics. Pharmgkb.org 2010. Available from: www.pharmgkb.org/do/serve?objId=PA145011109&objCIs=pathway. [Last accessed 20 November 2010]
   Google Scholar
• McKenney JA, Ganz P, Wiggins BS, Statins. In: Ballantyne CM, editor, Clinical Lipidology: a companion to Braunwald's Heart Disease. Saunders Elsevier, Philadelphia; 2009. p. 253-80
   Google Scholar
• Konig J, Cui Y, Nies AT, A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J physiol Gastrointest Liver Physiol 2000;278:156-64
   PubMed Web of Science ®Google Scholar
• Robey RW, To KK, Polgar O, ABCG2: a perspective. Adv Drug Deliv Rev 2009;61(1):1-3
   PubMedGoogle Scholar
• Backman JT, Kyrklund C, Kivisto KT, Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68:122-9
   PubMed Web of Science ®Google Scholar
• Kyrklund C, Backman JT, Neuvonen M, Gemfibrozil increases plasma pravastatin concentrations and reduces renal clearance. Clin Pharmacol Ther 2003;73:538-44
   PubMed Web of Science ®Google Scholar
• Schneck DW, Birmingham BK, Zalikowski JA, The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharamacol Ther 2004;75:455-63
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan SY, Cher Goh B, Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44:279-304
   PubMed Web of Science ®Google Scholar
• Peters BJM, Klungel OH, de Boer A, Genetic determinants of response to statins. Expert rev Cardiovasc Ther 2009;7(8):977-83
   PubMedGoogle Scholar
• Keskitalo JE, Zolk O, Fromm MF, ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009;86:197-203
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Pasanen MK, Neuvonen PJ, Different effects of the ABCG2 c.421C>A single nucleotide polymorphism on the pharmacokinetics of Fluvastatin, pravastatin, and simvastatin. Pharmacogenomics 2009;10:1617-24
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Kurkinen KJ, Neuvonen PJ, ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008;84(4):457-61
   PubMedGoogle Scholar
• Peters BJM, Rodin AS, Klungel OH, Pharmacogenetic interactions between ABCB1 and SLCO1B1 genes tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics 2010;11(8):1065-76
   PubMedGoogle Scholar
• Kajinami K, Brousseau ME, Ordovas JM, CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 2004;93(1):104-7
   PubMedGoogle Scholar
• Fiegenbaum M, da Silveira FR, van der Sand CR, The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005;78(5):551-8
   PubMedGoogle Scholar
• Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009;158:693-705
   PubMed Web of Science ®Google Scholar
• Wilke RA, Lin DW, Roden D, Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007;6(11):904-16
   PubMedGoogle Scholar
• Basic Concepts. In: Waller P, editor, An Introduction to Pharmacovigilance. Wiley-Blackwell, Oxford, UK; 2010. p. 15-29
   Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of 39 prospective studies. JAMA 1998;279:1200-05
   PubMed Web of Science ®Google Scholar
• Limdi NA, Veenstra DL. Expectations, validity, and reality in pharmacogenetics. J Clin Epidemiol 2010;63:960-9
   PubMedGoogle Scholar
• Guttmacher AE, Collins FS. Genomic medicine: a primer. N Engl J Med 2002;347:1512-20
   PubMed Web of Science ®Google Scholar
• Wang ET, Sandberg R, Luo S, Alternative isoforms regulation in human tissue transcriptomes. Nature 2008;456:470-6
   PubMed Web of Science ®Google Scholar
• Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA 2008;299(11):1335-44
   PubMed Web of Science ®Google Scholar
• Nordin C, Dahl ML, Eriksson M, Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphisms? Lancet 1997;350:29-30
   PubMed Web of Science ®Google Scholar
• Marez D, Legrand M, Sabbagh N, Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;7:193-202
   PubMedGoogle Scholar
• Mulder AB, van Lijf HJ, Bon MA, Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2001;70(6):546-51
   PubMedGoogle Scholar
• Zuccaro P, Mombelli G, Calabresi L, Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesterolaemic response to simvastatin and Fluvastatin. Pharmacol Res 2007;55:310-17
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 2003;56(1):120-4
   PubMedGoogle Scholar
• Quinzii C, Naini A, Salvatti L, A mutation in para-hydroxybenzoate-polyprenyl transferase (CoQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet 2006;78:345-9
   PubMed Web of Science ®Google Scholar
• Newman TB, Browner WS, Cummings SR, Designing an observational study: cross sectional and case-control studies. In: Hulley SB, , editors, Designing clinical research: an epidemiologic approach. Lippincott Williams & Wilkins, Philadelphia; 2001. p. 107-24
   Google Scholar
• Balding DJ. A tutorial on statistical methods for population association studies. Nature Reviews 2006;7:781-91
   Web of Science ®Google Scholar
• Rotimi CN, Jorde LB. Ancestry and disease in the age of genomic medicine. N Engl J Med 2010;363:1551-8
   PubMed Web of Science ®Google Scholar
• Peters BMJ, Rodin AS, de Boer A, Methodological and statistical issues in pharmacogenomics. JJP 2010;62:161-6
   Google Scholar
• Hansen NT, Brunak S, Altman RB. Generating genome-scale candidate gene lists for pharmacogenomics. Clin Pharmacol Ther 2009;86:183-9
   PubMed Web of Science ®Google Scholar
• Romaine SPR, Bailey KM, Hall AS, The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 2010;10:1-11
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Fredrikson H, Neuvonen PJ, Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007;82(6):726-33
   PubMed Web of Science ®Google Scholar
• Lee E, Ryan S, Birmingham B, Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78(4):330-41
   PubMed Web of Science ®Google Scholar
• Ho RH, Choi L, Lee W, Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics 2007;17(8):647-56
   PubMedGoogle Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16(12):873-9
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006;80:356-66
   PubMed Web of Science ®Google Scholar
• Morimoto K, Ueda S, Seki N, Candidate gene approach for the study of genetic factors involved in HMG-CoA-reductase inhibitors induced rhabdomyolysis [abstract]. Eighteenth JSSX Annual Meeting; 2003. p. 8PE-32
   Google Scholar
• Morimoto K, Oishi T, Ueda S, A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet 2004;19(6):453-5
   PubMedGoogle Scholar
• Morimoto K, Ueda S, Seki N, OATP-C(OATP01B1)*15 is associated with statin-induced myopathy in hypercholesterolemic patientsOATP. Clin PharmacoTher 2005;77:P21
   Google Scholar
• The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy - A genomewide study. N Engl J Med 2008;359:789-99
   PubMedGoogle Scholar
• Voora D, Shah Sh, Spasojevic I, The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16
   PubMed Web of Science ®Google Scholar
• Donnelly LA, Doney AS, Tavendale R, Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther 2011;89(2):210-16
   PubMedGoogle Scholar
• Manolio TA. Genomewide association studies and assessment of risk of disease. N Engl J Med 2010;363:166-76
   PubMed Web of Science ®Google Scholar
• Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97(Suppl):52C-60C
   PubMedGoogle Scholar
• McGreechan K, Macaskill P, Irwig L, Assessing new biomarkers and predictive models for use in clinical practice. Arch Intern Med 2008;168(21):2304-10
   PubMedGoogle Scholar
• Kameyama Y, Yamashita K, Kobayashi K, Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet 2005;15:513-22
   Google Scholar
• Hirano M, Maeda K, Shitara Y, Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004;311:139-46
   PubMed Web of Science ®Google Scholar
• Deng JW, Song IS, Shin HJ, The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 2008;18:424-33
   PubMed Web of Science ®Google Scholar
• Hsiang B, Zhu Y, Wang Z, A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver specific human organic anion transporting polypeptide and identification of rat and human hydroximethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999;274:37161-8
   PubMed Web of Science ®Google Scholar
• Simonson SG, Raza A, Martin PD, Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004;76:167-77
   PubMed Web of Science ®Google Scholar
• Ho RH, Tirona RG, Leake BF, Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006;130:1793-806
   PubMed Web of Science ®Google Scholar
• Chen C, Mireles RJ, Campbell SD, Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 2005;33:537-46
   PubMed Web of Science ®Google Scholar
• Shitihara Y, Hirano M, Sato H, Gemfibrozil and its glucorunide inhibit the anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004;311:228-36
   PubMedGoogle Scholar
• Noe J, Portmann R, Brun ME, Substrate-dependent drug-drug interactions between gemfibrozil, Fluvastatin and other organic anion transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 2007;35:1308-14
   PubMed Web of Science ®Google Scholar